PL3599237T3 - Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta - Google Patents

Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta

Info

Publication number
PL3599237T3
PL3599237T3 PL19182732T PL19182732T PL3599237T3 PL 3599237 T3 PL3599237 T3 PL 3599237T3 PL 19182732 T PL19182732 T PL 19182732T PL 19182732 T PL19182732 T PL 19182732T PL 3599237 T3 PL3599237 T3 PL 3599237T3
Authority
PL
Poland
Prior art keywords
eliglustat
metabolism
patient
adjustment
treatment
Prior art date
Application number
PL19182732T
Other languages
English (en)
Inventor
Hanlan Liu
Chris Willis
Renu Bhardwaj
Diane P. Copeland
Abizer Harianawala
Jeffrey Skell
John Marshall
Jianmei Kochling
Gerard Palace
Judith Peterschmitt
Craig Siegel
Seng Cheng
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43431870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3599237(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3599237T3 publication Critical patent/PL3599237T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
PL19182732T 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta PL3599237T3 (pl)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US26474809P 2009-11-27 2009-11-27
EP19182732.8A EP3599237B1 (en) 2009-11-27 2010-11-24 Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment of gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
EP10785289.9A EP2504332B2 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP14164650.5A EP2796457B1 (en) 2009-11-27 2010-11-24 Genz 112638 for treating Gaucher or Fabry disease in combination therapy
EP16175117.7A EP3133070B1 (en) 2009-11-27 2010-11-24 Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient
PCT/US2010/057952 WO2011066352A1 (en) 2009-11-27 2010-11-24 An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
EP16159714.1 2016-03-10

Publications (1)

Publication Number Publication Date
PL3599237T3 true PL3599237T3 (pl) 2021-09-27

Family

ID=43431870

Family Applications (4)

Application Number Title Priority Date Filing Date
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej
PL19182732T PL3599237T3 (pl) 2009-11-27 2010-11-24 Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL16175117T PL3133070T3 (pl) 2009-11-27 2010-11-24 Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
PL10785289T PL2504332T5 (pl) 2009-11-27 2010-11-24 Amorficzna i krystaliczna postać hemiwinianu genz 112638 jako inhibitor syntazy glukozyloceramidowej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14164650T PL2796457T3 (pl) 2009-11-27 2010-11-24 Genz 112638 do leczenia w terapii skojarzonej choroby Gauchera lub choroby Fabry’ego

Country Status (40)

Country Link
US (6) US11458119B2 (pl)
EP (5) EP2504332B2 (pl)
JP (6) JP2013512252A (pl)
KR (6) KR20200013105A (pl)
CN (5) CN102712629B (pl)
AR (3) AR079152A1 (pl)
AU (3) AU2010324810B2 (pl)
BR (1) BR112012012947B8 (pl)
CA (3) CA2781676C (pl)
CL (2) CL2012001348A1 (pl)
CR (1) CR20120277A (pl)
CY (3) CY1115880T1 (pl)
DK (3) DK2796457T3 (pl)
DO (2) DOP2012000141A (pl)
EA (3) EA201890254A3 (pl)
EC (2) ECSP12011926A (pl)
ES (4) ES2875382T3 (pl)
GT (1) GT201200161A (pl)
HR (3) HRP20140780T4 (pl)
HU (2) HUE029371T2 (pl)
IL (4) IL310635A (pl)
LT (2) LT3133070T (pl)
MA (1) MA33838B1 (pl)
ME (1) ME02477B (pl)
MX (2) MX381242B (pl)
MY (2) MY192644A (pl)
NI (1) NI201200096A (pl)
NZ (3) NZ625712A (pl)
PE (2) PE20171255A1 (pl)
PH (2) PH12012501048A1 (pl)
PL (4) PL3133070T3 (pl)
PT (4) PT3599237T (pl)
RS (3) RS54978B1 (pl)
SG (2) SG10201800136QA (pl)
SI (3) SI2504332T2 (pl)
SM (1) SMT201600273B (pl)
TN (1) TN2012000237A1 (pl)
TW (3) TWI586663B (pl)
UA (1) UA113491C2 (pl)
WO (1) WO2011066352A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889127B2 (en) 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
CN103764824B (zh) * 2011-06-20 2018-04-24 西奈山医学院 粘多糖贮积症和其它溶酶体病症的抗TNF-α疗法
DK2753346T3 (da) 2011-09-07 2020-05-25 Sinai School Medicine Ceramidase og celledifferentiering
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP2854910B1 (en) 2012-06-01 2020-04-15 Icahn School of Medicine at Mount Sinai Ceramide levels in the treatment and prevention of infections
EP3659619A1 (en) 2013-03-14 2020-06-03 Icahn School of Medicine at Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
TWI690511B (zh) * 2013-09-20 2020-04-11 美商拜奧馬林製藥公司 用於治療疾病之葡萄糖苷基腦醯胺（ｇｌｕｃｏｓｙｌｃｅｒａｍｉｄｅ）合成酶抑制劑
US20170129869A1 (en) * 2014-07-03 2017-05-11 Dr. Reddy's Laboratories Limited Amorphous form of eliglustat hemitartarate
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
EP3377908B1 (en) 2015-11-18 2020-08-05 Genzyme Corporation Biomarker of polycystic kidney disease and uses thereof
SG11201807012QA (en) 2016-02-25 2018-09-27 Asceneuron S A Acid addition salts of piperazine derivatives
CN107445938B (zh) * 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
MX2019015177A (es) 2017-06-16 2020-02-07 Beta Pharma Inc Formulaciones farmaceuticas de n-(2-(2-(dimetilamino)etoxi)-4-meto xi-5((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilam ida y las sales de ellas.
DK3664798T3 (da) * 2017-08-08 2026-02-02 Amneal Pharmaceuticals Llc Farmaceutisk sammensætning der omfatter eliglustat
US12472144B2 (en) * 2017-08-08 2025-11-18 Amneal Pharmaceuticals Llc Pharmaceutical composition comprising eliglustat
WO2019118707A1 (en) 2017-12-15 2019-06-20 Genzyme Corporation Methods for treating gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
US11760741B2 (en) 2018-05-02 2023-09-19 Kashiv Biosciences, Llc Pro-drugs of eliglustat
CN112512558A (zh) * 2018-05-27 2021-03-16 比奥阿赛斯技术有限公司 戈谢病的治疗
CN110878079A (zh) * 2018-12-31 2020-03-13 北京启慧生物医药有限公司 一种高纯度依利格鲁司他的制备方法
IL309862A (en) * 2021-07-05 2024-02-01 Ferrer Int Medicines that include glycosidase inhibitors
CN116120274A (zh) * 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US5707649A (en) 1993-08-13 1998-01-13 Seikagaku Corporation Agent for treating neuronal diseases
US6309823B1 (en) 1993-10-26 2001-10-30 Affymetrix, Inc. Arrays of nucleic acid probes for analyzing biotransformation genes and methods of using the same
ATE195944T1 (de) 1994-02-02 2000-09-15 Liposome Co Inc Pharmazeutisch wirksame verbindungen und liposome und verfahren zu deren herstellung
WO1995034530A1 (en) 1994-06-10 1995-12-21 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
ES2285852T3 (es) 1998-07-27 2007-11-16 Johns Hopkins University Compuestos de diamino-propanol para el tratamiento de la isquemia.
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
EP1384719A1 (en) 1999-07-09 2004-01-28 The Regents of The University of Michigan Inhibitors of the glucosyl ceramide synthase enzyme useful for the treatment of cancers, sphingolipidosis and microbial infections
EP1196406A1 (en) * 1999-07-09 2002-04-17 The Regents of the University of Michigan Amino ceramide-like compounds and therapeutic methods of use
NZ519984A (en) * 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US20040252299A9 (en) 2000-01-07 2004-12-16 Lemmo Anthony V. Apparatus and method for high-throughput preparation and spectroscopic classification and characterization of compositions
ATE335481T1 (de) 2000-04-24 2006-09-15 Teva Pharma Zolpidem hemitartrat solvat
US6436987B1 (en) 2000-06-08 2002-08-20 Pfizer Inc. Crystalline forms of (3S-trans)-2-[3,4-dihydro-4-hydroxy-3-(phenylmethyl)-2H-1-benzopyran-7-yl]-4-(trifluoromethyl)-benzoic acid
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
CA2434028C (en) 2001-01-10 2010-11-09 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
CN1630720A (zh) * 2001-01-18 2005-06-22 默克专利有限公司 具有葡糖脑苷脂酶活性的双功能融合蛋白
EP2266968B1 (en) * 2001-07-16 2013-01-09 Genzyme Corporation Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
EP1281755A3 (en) 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
DE60235632D1 (de) 2001-08-08 2010-04-22 Tobira Therapeutics Inc Bicyclische verbindung, deren herstellung und verwendung
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
JP2005535665A (ja) 2002-07-09 2005-11-24 ザ スクリプス リサーチ インスティテュート 虚血および再灌流損傷を防止する方法
US20050032070A1 (en) 2003-08-05 2005-02-10 Sebastian Raimundo Polymorphisms in the human gene for CYP2D6 and their use in diagnostic and therapeutic applications
EP1709053B1 (en) * 2004-01-27 2011-04-06 Synthon B.V. Stable salts of olanzapine
ES2375995T3 (es) 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
CA3113166A1 (en) 2004-09-30 2006-04-13 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
WO2006040649A1 (en) 2004-10-13 2006-04-20 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
CA2586761A1 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
WO2007038676A2 (en) * 2005-09-28 2007-04-05 Teva Pharmaceutical Industries Ltd. Polymorphic forms of ladostigil tartrate
JP2009510163A (ja) * 2005-10-03 2009-03-12 マリンクロッド・インコーポレイテッド ヘミ酒石酸および酒石酸ゾルピデム多形の製造方法
MX2007016179A (es) 2006-04-17 2008-03-11 Teva Pharma Formas cristalinas de o-desmetilvenlafaxina.
EP2032134B1 (en) * 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
KR101271225B1 (ko) 2006-10-31 2013-06-03 삼성디스플레이 주식회사 발광 다이오드 칩 및 발광 다이오드 광원 모듈의 제조 방법
TWI314226B (en) 2006-12-07 2009-09-01 Ind Tech Res Inst Piezoelectricity-driving optical lens module
EP1961765A1 (en) * 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
BRPI0806543A2 (pt) * 2007-01-12 2014-04-22 Wyeth Corp Composições de comprimido em comprimido
CA2682441A1 (en) * 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US8304447B2 (en) * 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
DE102007029581B4 (de) 2007-06-26 2020-04-09 GM Global Technology Operations LLC (n. d. Ges. d. Staates Delaware) Kraftfahrzeugdach und Kraftfahrzeugkarosserie
US20090307180A1 (en) 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
HUE026778T2 (en) 2009-11-27 2016-08-29 Adverio Pharma Gmbh Method for producing methyl- {4,6-diamino-2-[1-(2-fluorobenzyl) -1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidin-5-yl}-methyl carbamate and its purification for its use as a pharmaceutical agent
PL3133070T3 (pl) 2009-11-27 2020-01-31 Genzyme Corporation Eliglustat (Genz 112638) jako inhibitor syntazy glukozyloceramidowej do zastosowania w sposobie leczenia choroby Fabry’ego lub choroby Gauchera, przy czym sposób obejmuje dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 u pacjenta
FR2953139B1 (fr) 2009-11-27 2012-04-13 Servier Lab Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine
EP2504002B1 (en) 2009-11-27 2019-10-09 Boehringer Ingelheim International GmbH Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
KR20140033432A (ko) 2011-06-21 2014-03-18 노파르티스 아게 (s)-피롤리딘-1,2-디카르복실산 2-아미드 1-(｛4-메틸-5-[2-(2,2,2-트리플루오로-1,1-디메틸-에틸)-피리딘-4-일]-티아졸-2-일｝-아미드)의 다형체
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
JP6728842B2 (ja) 2016-03-24 2020-07-22 オムロン株式会社 光学計測装置
CN107445938B (zh) 2016-05-31 2020-04-03 北京启慧生物医药有限公司 依利格鲁司他半酒石酸盐的结晶形式、制备方法和含有所述结晶形式的药用组合物
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof

Also Published As

Publication number Publication date
JP2013512252A (ja) 2013-04-11
EA201592195A1 (ru) 2016-04-29
JP2023116764A (ja) 2023-08-22
PH12015502514A1 (en) 2016-08-15
TWI606827B (zh) 2017-12-01
US20210393590A1 (en) 2021-12-23
HUE045784T2 (hu) 2020-01-28
NZ715108A (en) 2017-06-30
CN105777707B (zh) 2020-10-13
US20210369672A1 (en) 2021-12-02
CR20120277A (es) 2012-09-05
JP6452635B2 (ja) 2019-01-16
JP2016138124A (ja) 2016-08-04
MX381242B (es) 2025-03-12
HK1203485A1 (en) 2015-10-30
HRP20140780T4 (hr) 2021-08-06
RS59543B1 (sr) 2019-12-31
TW201639562A (zh) 2016-11-16
CN112521367B (zh) 2024-01-02
PH12012501048A1 (en) 2013-02-04
PH12015502514B1 (en) 2022-07-29
KR20200013105A (ko) 2020-02-05
AU2010324810A1 (en) 2012-06-07
EP2504332A1 (en) 2012-10-03
MY160542A (en) 2017-03-15
BR112012012947B1 (pt) 2021-04-06
PL2504332T5 (pl) 2021-08-23
AU2016202591B2 (en) 2017-11-30
ECSP12011926A (es) 2012-07-31
EP3599237A1 (en) 2020-01-29
SMT201600273B (it) 2016-08-31
AU2017265180B2 (en) 2019-08-01
SI2796457T1 (sl) 2016-10-28
SG10201407881WA (en) 2015-01-29
HRP20191647T1 (hr) 2019-12-13
DOP2012000141A (es) 2012-09-30
PT2504332E (pt) 2014-09-02
CA3075788A1 (en) 2011-06-03
TWI586663B (zh) 2017-06-11
CA2781676C (en) 2020-05-05
KR20120115972A (ko) 2012-10-19
DK2504332T4 (da) 2021-06-07
NI201200096A (es) 2012-10-30
CL2012001348A1 (es) 2012-08-24
MX2012006083A (es) 2012-06-19
PT3133070T (pt) 2019-11-11
PT3599237T (pt) 2021-04-28
SG10201800136QA (en) 2018-02-27
UA113491C2 (xx) 2017-02-10
CN102712629A (zh) 2012-10-03
JP7150528B2 (ja) 2022-10-11
US11458119B2 (en) 2022-10-04
EP2504332B2 (en) 2021-03-17
IL283935A (en) 2021-07-29
US10888547B2 (en) 2021-01-12
HRP20161038T1 (hr) 2016-10-21
CY1117996T1 (el) 2017-05-17
LT2796457T (lt) 2016-09-12
ECSP18063798A (es) 2020-02-28
ME02477B (me) 2017-02-20
EA023923B1 (ru) 2016-07-29
KR20180049255A (ko) 2018-05-10
EP3133070B1 (en) 2019-08-14
EA201890254A2 (ru) 2018-10-31
PL3133070T3 (pl) 2020-01-31
AU2016202591A1 (en) 2016-05-19
KR102073207B1 (ko) 2020-02-05
MX358345B (es) 2018-08-14
NZ625712A (en) 2016-02-26
PE20121337A1 (es) 2012-10-12
SI2504332T1 (sl) 2014-09-30
AU2010324810B2 (en) 2016-05-12
CN105753846A (zh) 2016-07-13
CA2781676A1 (en) 2011-06-03
WO2011066352A1 (en) 2011-06-03
AU2017265180A1 (en) 2017-12-14
ES2493940T5 (es) 2021-11-23
EP2504332B1 (en) 2014-06-04
US20160166542A1 (en) 2016-06-16
HRP20140780T1 (en) 2014-11-07
ES2493940T3 (es) 2014-09-12
ES2586947T3 (es) 2016-10-19
CN102712629B (zh) 2016-10-12
JP2015212291A (ja) 2015-11-26
JP2020189873A (ja) 2020-11-26
AR079152A1 (es) 2011-12-28
TN2012000237A1 (en) 2013-12-12
KR20150125734A (ko) 2015-11-09
BR112012012947A2 (pt) 2017-03-01
KR20220162824A (ko) 2022-12-08
US20130137743A1 (en) 2013-05-30
CY1122698T1 (el) 2021-03-12
PT2796457T (pt) 2016-07-14
CN105753846B (zh) 2019-11-15
CA3140959A1 (en) 2011-06-03
NZ600155A (en) 2014-10-31
WO2011066352A8 (en) 2011-08-11
ES2875382T3 (es) 2021-11-10
AR121611A2 (es) 2022-06-22
CN105777707A (zh) 2016-07-20
DK2796457T3 (en) 2016-08-29
RS54978B1 (sr) 2016-11-30
EP2796457B1 (en) 2016-05-18
EA201270646A1 (ru) 2013-01-30
RS53503B2 (sr) 2021-07-30
PL2796457T3 (pl) 2017-04-28
TW201737910A (zh) 2017-11-01
DK2504332T3 (da) 2014-08-25
CN112521366A (zh) 2021-03-19
US20160120842A1 (en) 2016-05-05
IL310635A (en) 2024-04-01
JP2019001809A (ja) 2019-01-10
CN112521367A (zh) 2021-03-19
IL219892A0 (en) 2012-07-31
US20230172903A1 (en) 2023-06-08
EA029990B1 (ru) 2018-06-29
CL2016002589A1 (es) 2017-05-19
BR112012012947B8 (pt) 2021-05-25
HUE029371T2 (en) 2017-02-28
LT3133070T (lt) 2019-11-11
US12465586B2 (en) 2025-11-11
KR20250005503A (ko) 2025-01-09
ES2754398T3 (es) 2020-04-17
GT201200161A (es) 2014-01-27
EP3133070A1 (en) 2017-02-22
PL2504332T3 (pl) 2014-10-31
EA201890254A3 (ru) 2019-02-28
DK3133070T3 (da) 2019-11-11
SI3133070T1 (sl) 2019-11-29
IL260299A (en) 2018-08-30
RS53503B1 (sr) 2015-02-27
CY1115880T1 (el) 2017-01-25
MA33838B1 (fr) 2012-12-03
AR121612A2 (es) 2022-06-22
PE20171255A1 (es) 2017-08-28
SI2504332T2 (sl) 2021-08-31
CA3075788C (en) 2021-12-21
HK1172031A1 (en) 2013-04-12
JP6370264B2 (ja) 2018-08-08
EP2796457A1 (en) 2014-10-29
DOP2016000250A (es) 2017-02-15
MY192644A (en) 2022-08-29
TW201130822A (en) 2011-09-16
EP3896069A1 (en) 2021-10-20
EP3599237B1 (en) 2021-03-24
TWI656873B (zh) 2019-04-21

Similar Documents

Publication Publication Date Title
PL3599237T3 (pl) Kompozycja farmaceutyczna inhibitora syntazy glukozyloceramidowej eliglustatu do leczenia choroby Gauchera obejmującego dostosowanie indywidualnej dawki terapeutycznej do metabolizmu P450 pacjenta
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
UY32919A (es) Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
IL193727A0 (en) Dosage forms for administering combinations of drugs
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
IN2012DN06720A (pl)
PT2510916T (pt) Composição farmacêutica antisséptica para a higiene oral e o tratamento de doenças bucais de origem microbiana
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
IL211293A (en) Combination factors for the preparation of a drug for the treatment of tuberculosis
IL216468B (en) Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases
PL2464342T3 (pl) Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych
IL202083A0 (en) Pharmaceutical compositions and methods for enhancing targeting of therapeutic compounds to the central nervous system
UY33370A (es) Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización
EP2396073A4 (en) IONTOPHORETIC SYSTEM FOR THE TRANSDERMAL ACTIVE SUBSTANCE FOR THERAPEUTIC AND MEDICAL USE
EP2506850A4 (en) METHOD FOR THE ADMINISTRATION OF PIRFENIDON THERAPY
EP2453886A4 (en) PHARMACEUTICAL PRODUCT FOR ORAL ADMINISTRATION COMPRISING MGBG AND METHODS OF TREATING DISEASE
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
IL202111A0 (en) Formulations for the oral administration of therapeutic agents and related methods
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
WO2009099553A3 (en) Use of kinase inhibitor in treatment of atherosclerosis
EP2168586A4 (en) ACTIVE AGENT, REMEDY, PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF PATIENTS WITH DENTAL SYNDROME
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT